13-Mar-2025 3:05 PM CST - Business Wire Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the following virtual investor conferences: UBS Virtual CNS Day 2025 Fireside Chat: Monday, March 17, 2025 at 11:00 a.m. Eastern Time Stifel 2025 Virtual CNS Forum Fireside Chat: Wednesday, March 19, 2025 at 12:30 p.m. Eastern Time 24th Annual Needham Virtual Healthcare Conference Fireside Chat: Monday, April 7, 2025 at 10:15 a.m. Eastern Time Live webcasts of each fireside chat wi
26-Feb-2025 3:05 PM CST - Business Wire Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the fourth quarter and full year ended December 31, 2024. We closed 2024 on a strong note with each of our brands achieving record revenues in the fourth quarter and well-positioned for continued growth in 2025, said Catherine Owen Adams, Chief Executive Officer. To support this growth in 2025 we will continue investing in consumer activation to drive market share expansion for NU
12-Feb-2025 3:05 PM CST - Business Wire Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, February 26, 2025, after the close of the U.S. financial markets. Acadias management team will also host a conference call and webcast on February 26, 2025, at 4:30 p.m. Eastern Time. The webcast will be available on Acadias website, Acadia.com under the investors section and will be archived there until May 26, 2025. The
14-Jan-2025 8:05 AM CST - Business Wire Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced multiple business updates and progress on the Company's CNS and rare disease drug candidates, which will be discussed today during a presentation by Catherine Owen Adams, Chief Executive Officer, at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. 2025 is shaping up to be an exciting year as we build on the success of our two growing brands, NUPLAZID and DAYBUE, which together are proj
19-Dec-2024 3:05 PM CST - Business Wire Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025 Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Catherine Owen Adams, Chief Executive Officer will represent the Company in a session scheduled on Tuesday, January 14, 2025, at 9:00 a.m. Pacific Time / 12:00 p.m. Eastern Time. A live webcast of Acadias presentation will be accessible on the companys website, Acadia.com, under the investors section and an archi
21-Nov-2024 3:05 PM CST - Business Wire Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences: Citi's 2024 Global Healthcare Conference Fireside Chat: Tuesday, December 3, 2024 at 10:15 a.m. Eastern Time in Miami, FL 7th Annual Evercore HealthCONx Conference Fireside Chat: Wednesday, December 4, 2024 at 2:35 p.m. Eastern Time in Coral Gables, FL Live webcasts of each fireside chat will be accessible on the companys website, Acadia.com, und
6-Nov-2024 3:05 PM CST - Business Wire Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the third quarter ended September 30, 2024. The success of Acadias two growing commercial franchises is clearly reflected in our third quarter 2024 results, where we delivered $250.4 million in total revenues, putting us on track to reach an impressive milestone of more than $1 billion in annualized sales in 2025, said Catherine Owen Adams, Chief Executive Officer. In my new role
17-Oct-2024 5:41 PM CST - Business Wire Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024 Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter financial results on Wednesday, November 6, 2024, after the close of the U.S. financial markets. Acadias management team will also host a conference call and webcast on November 6, 2024, at 4:30 p.m. Eastern Time to discuss financial results and operations. The conference call will be available on Acadias website, Acadia.com under the investors section and will be archived
13-Mar-2025 3:05 PM CST - Business Wire Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the following virtual investor conferences: UBS Virtual CNS Day 2025 Fireside Chat: Monday, March 17, 2025 at 11:00 a.m. Eastern Time Stifel 2025 Virtual CNS Forum Fireside Chat: Wednesday, March 19, 2025 at 12:30 p.m. Eastern Time 24th Annual Needham Virtual Healthcare Conference Fireside Chat: Monday, April 7, 2025 at 10:15 a.m. Eastern Time Live webcasts of each fireside chat wi
26-Feb-2025 3:05 PM CST - Business Wire Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the fourth quarter and full year ended December 31, 2024. We closed 2024 on a strong note with each of our brands achieving record revenues in the fourth quarter and well-positioned for continued growth in 2025, said Catherine Owen Adams, Chief Executive Officer. To support this growth in 2025 we will continue investing in consumer activation to drive market share expansion for NU
12-Feb-2025 3:05 PM CST - Business Wire Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, February 26, 2025, after the close of the U.S. financial markets. Acadias management team will also host a conference call and webcast on February 26, 2025, at 4:30 p.m. Eastern Time. The webcast will be available on Acadias website, Acadia.com under the investors section and will be archived there until May 26, 2025. The
14-Jan-2025 8:05 AM CST - Business Wire Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced multiple business updates and progress on the Company's CNS and rare disease drug candidates, which will be discussed today during a presentation by Catherine Owen Adams, Chief Executive Officer, at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. 2025 is shaping up to be an exciting year as we build on the success of our two growing brands, NUPLAZID and DAYBUE, which together are proj
19-Dec-2024 3:05 PM CST - Business Wire Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025 Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Catherine Owen Adams, Chief Executive Officer will represent the Company in a session scheduled on Tuesday, January 14, 2025, at 9:00 a.m. Pacific Time / 12:00 p.m. Eastern Time. A live webcast of Acadias presentation will be accessible on the companys website, Acadia.com, under the investors section and an archi
21-Nov-2024 3:05 PM CST - Business Wire Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences: Citi's 2024 Global Healthcare Conference Fireside Chat: Tuesday, December 3, 2024 at 10:15 a.m. Eastern Time in Miami, FL 7th Annual Evercore HealthCONx Conference Fireside Chat: Wednesday, December 4, 2024 at 2:35 p.m. Eastern Time in Coral Gables, FL Live webcasts of each fireside chat will be accessible on the companys website, Acadia.com, und
6-Nov-2024 3:05 PM CST - Business Wire Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the third quarter ended September 30, 2024. The success of Acadias two growing commercial franchises is clearly reflected in our third quarter 2024 results, where we delivered $250.4 million in total revenues, putting us on track to reach an impressive milestone of more than $1 billion in annualized sales in 2025, said Catherine Owen Adams, Chief Executive Officer. In my new role
17-Oct-2024 5:41 PM CST - Business Wire Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024 Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter financial results on Wednesday, November 6, 2024, after the close of the U.S. financial markets. Acadias management team will also host a conference call and webcast on November 6, 2024, at 4:30 p.m. Eastern Time to discuss financial results and operations. The conference call will be available on Acadias website, Acadia.com under the investors section and will be archived
